Stipple Bio

Private

Precision oncology biotech harnessing epitope-level precision to create targeted cancer therapies. The Pointillist Platform identifies tumor-specific cell surface epitopes, enabling antibody-drug conjugates (ADCs) that avoid on-target/off-tumor toxicity. Lead candidate STP-100 expected in clinical studies early 2027.

Founders Aaron Ring, Aashish Manglik

CEO Aaron Ring

Company

Founded

2022

Headquarters

Cambridge, United States

Financials

Total Funding

$100M

Sectors

Artificial Intelligence Healthtech Biotech

stipple.bio

Funding History

1 round

Series A Apr 6, 2026

$100M

RA Capital (Lead) Andreessen Horowitz Nextech Invest

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.